Maria Bagniewska

Led enterprise-scale strategic direction, analytics product governance, and operational foundations for the 1,000+ person gRED AI/ML Computational Sciences organization (Prescient Design, Infrastructure/ Architecture, Computational Biology) • Oversaw integrated portfolios across Program & Portfolio Strategy, Business Operations, and Data-Driven Governance, ensuring alignment with Genentech’s broader digital and AI/ML transformation goals. • Designed and managed the full lifecycle of portfolio initiatives, delivering measurable scientific and business impact across R&D. Drove prioritization and resource allocation through scalable, transparent governance frameworks. • Connected scientific, data, engineering, and informatics teams to surface high-value analytics opportunities. • Championed operational and technical innovation to streamline decision-making and drive performance at the pipeline and enterprise level. • Built deep partnerships across gRED, pRED, PD, Informatics, and Global Functions and translated complex science and data into actionable strategies for leadership across therapeutic areas. • Led business continuity planning and performance optimization efforts at scale.

Served as a strategic advisor to Manta Ray Ventures, an early-stage venture capital fund backed by Kulczyk Investments, with a focus on high-impact, mission-driven biotech and health innovations. Provided in-depth technical, scientific, and strategic due diligence for Seed to Series B investment opportunities across the global healthcare ecosystem. • Partnered with founding teams and the investment committee to assess the translational potential, business models, and scalability of innovative life sciences startups, contributing to capital deployment strategies aligned with long-term societal value creation. • Supported portfolio development in areas such as synthetic biology, precision medicine, and AI-enabled healthcare platforms.

Promoted through three leadership roles, overseeing the strategic transformation, integration, and execution of Amunix’s R&D portfolio within Sanofi’s Global Research organization.

Program and Portfolio Management function creation. Led all Program/ Portfolio management and expansion plans for a successful $1B+ M&A deal with Sanofi. Hired high-performing PM Team to support all aspects of Program Management and Portfolio Operations.

Heading the Program Portfolio Management Team to develop and execute on the portfolio strategy, delivering novel tumor-targeting therapeutics to patients. Amunix aims to mitigate the toxicity of T cell engagers (TCEs) and cytokine therapies by creating drugs that are preferentially activated in the tumor microenvironment, thus driving tumor cell killing while minimizing toxicity that can damage healthy tissues.

Spearheaded R&D and strategic portfolio expansion for LabGenius, a cutting-edge, venture-backed biotech startup leveraging machine learning and protein engineering to discover next-generation protein therapeutics. Operated at the intersection of AI, biotechnology, and business strategy to drive innovation and organizational growth. • Owned the design and execution of integrated Program Development Plans across a multidisciplinary R&D portfolio. • Defined scope, milestones, and operating models to support efficient resourcing and high-impact project delivery. • Led strategic collaborations with top-tier global pharmaceutical companies to co-develop advanced protein therapeutics via LabGenius’ proprietary AI platform. • Oversaw the full lifecycle of all R&D programs, from asset inception to partnership enablement, through robust tracking, reporting, and portfolio governance. • Served on the Executive Leadership Team, directly managing six Team Leads across molecular biology, protein production, NGS, automation, software engineering, and AI/ML.

• Delivered best-in-class personalized healthcare to patients by guiding the strategy, development and implementation of multiple companion diagnostics in support of extensive Roche/Genentech early (Phase I-II) and late stage (Phase III) therapeutic portfolios. • Cross-functional Team Leader and Project Manager with experience in In Vitro Diagnostics (IVD) and Companion Diagnostic (CDx) development strategy and implementation (lead on new indications for Atezolizumab and one early stage program).

Conducted collaborative translational research across gRED, driving internal programs (Proteomics, Physiological Chemistry, Translational Oncology) and an external partnership with Constellation Pharmaceuticals to explore T-cell targeting in cancer. • Supported foundational discoveries that informed early-stage therapeutic strategies.

Formerly Cancer Research UK, London Research Institute Signalling and Transcription Laboratory

LMB, Structural Studies Division, Crystallographic and Biochemical studies